- 1 **Title:** Healthcare seeking behavior and delays in case of drug-resistant Tuberculosis
- 2 patients in Bangladesh: Findings from a cross-sectional survey
- 3 Authors
- 4 1. Md. Zulqarnine Ibne Noman<sup>1,2</sup>
- 5 2. Shariful Islam<sup>2</sup>
- 6 3. Shaki Akter<sup>1,3</sup>
- 7 4. Ateeb Ahmad Parray 1,5\*
- 8 5. Dennis G Amando 1
- 9 6. Jyoti Karki<sup>1</sup>
- 10 7. Zafria Atsna 1
- 11 8. Dipak Mitra 4
- 12 9. Shaikh A. Shahed Hossain<sup>1</sup>
- 13 Affiliation
- 14 **1.** BRAC James P. Grant School of Public Health (JPGSPH), BRAC university, Dhaka-
- 15 1212, Bangladesh
- 2. EcoHealth Alliance Bangladesh Programs, Institute of Epidemiology, Disease
- 17 Control and Research (IEDCR), Dhaka 1212, Bangladesh
- 3. International Centre for Diarrhoeal Disease Research (icddr,b), Bangladesh, Dhaka,
- 19 Bangladesh
- 20 4. Department of Public Health, North South University, Dhaka, Bangladesh
- 21 5. Department of International Health, Health systems program, The Johns Hopkins
- 22 University Baltimore USA NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

\*Corresponding Author

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

40

42

Email – ahmad.ateeb101@gmail.com

**Keywords** – Care seeking, drug-resistant Tuberculosis, Patient delay, Diagnostic delay,

Treatment delay, Total delay, Bangladesh

Acknowledgements

The study was conducted under Summative Learning Project (SLP), as a partial requirement

of MPH degree at BRAC James P Grant School of Public Health, BRAC University. This work

has been funded by collectively by BRAC James P Grant School of Public Health, BRAC

University and TDR under grant number: B40297, the Special Programme for Research and

Training in Tropical Diseases, which is hosted at the World Health Organization and co-

sponsored by UNICEF, UNDP, the World Bank and WHO. We are also indebted towards Dr.

Aung, Country director, Damien foundation and Dr. Abdul Hamid Selim, Sr. Scientist,

National Tuberculosis and Leprosy control Programme, Ministry of Health and family

welfare, Govt. of People's Republic of Bangladesh for their full-on cooperation during the

timeframe of the study.

## **Competing Interests**

39 The authors have declared no competing interests.

### Conflict of Interests

The authors have declared no conflict of interests.

Abstract

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

**Background:** The emergence of Drug-Resistant Tuberculosis (DR-TB) has become a major threat globally and Bangladesh is no exception. Delays in healthcare seeking, proper diagnosis and initiation of treatment cause continuous transmission of the resistant tubercule bacilli through the communities. This study aimed to assess the different health care-seeking behaviors and delays among DR-TB patients in Bangladesh. **Method:** A prospective cross-sectional study was conducted from November to December 2018, among 92 culture positive and registered DR-TB patients in four selected hospitals in Bangladesh. Data were collected through face-to-face interviews with survey questionnaire as well as record reviews. Result: Among the 92 study participants, the median patient delay was 7 (IQR 3, 15) days, the median diagnostic delay was 88 (IQR 36.5, 210), the median treatment delay was 7 (IQR 4,12) days, and the median total delay among DR-TB patients was 108.5 (IQR 57.5, 238) days. 81.32% sought initial care from informal healthcare providers. The majority (68.48%) of the informal healthcare providers were drug sellers while 60.87% of patients sought care from more than four healthcare points before being diagnosed with DR-TB. The initial care seeking from multiple providers was associated with diagnostic and total delays. Conclusion: In Bangladesh, DR-TB cases usually seek care from multiple providers, particularly from informal providers, and among them, alarmingly higher healthcare-seeking related delays were noted. Immediate measures should be taken both at the health system levels and, in the community, to curb transmission and reduce the burden of the disease.

#### Introduction

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

Tuberculosis (TB) is a highly transmissible disease caused by Mycobacterium tuberculosis bacilli, the second most infectious killer after the COVID-19 pandemic and the 13<sup>th</sup> leading cause of overall mortality around the world (1). It is estimated that about a guarter of the world's population is already infected with TB though only 10% of them develop clinical TB during their lifetime (1) (2). The END TB-2030 strategy was developed with a vision of reducing the number of TB death by 90% and reduction of new cases by 80% (3). However, the emergence of drug-resistant tuberculosis (DR-TB) has become a global threat and challenges the End TB-2030 strategy as only one of four new DR-TB cases are now detected while one of two cases got cured (3). DR-TB is a clinical condition where any of the first-line anti-TB drugs is found resistant. It can be categorized as single-drug-resistant, multi-drug-resistant, or extensive drug-resistant (4). Multi-drug resistant tuberculosis (MDR-TB) is the most common form of DR-TB which is resistant to first-line anti-TB drugs Rifampicin (RFP) and Isoniazid (INR). When one fluoroquinolone and a second-line injectable drug are also resistant, then it is categorized as extensive/extreme drug-resistant tuberculosis (XDR-TB) also known as super-bugs, which may facilitate a global tubercular apocalypse, if not prevented, and intervened timely (5) (6). About 157 thousand incident cases of DR-TB were notified, and 150 thousand new cases were enrolled in treatment in 2020 according to the Global TB report. However, the estimated number of new cases of DR-TB is 500 thousand each year while only one of the three cases was treated (7). There was a 22% fall in new case detection and a 15% fall in new enrollment in DR-TB treatment from 2019 due to the COVID-19 pandemic. However, only one of three newly developed DR-TB cases each year are enrolled for treatment (1). The undiagnosed, late diagnosed, and lately treated cases cause the continuous spreading of resistant bacilli in

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

the community(8). The high risk of transmission, high case fatality, prolonged treatment, financial, and social burden make DR-TB control strategy more complicated for low and middle socio-income countries like Bangladesh (9). Bangladesh is one of the leading TB burden countries among the top 30 countries (10). In 2020, the laboratory-confirmed number of new DR-TB cases in Bangladesh was 1113, and the incidence rate of DR TB was 2% according to the Global TB report 2020(9). Early diagnosis of DR-TB and timely initiation of treatment are important. Any delays in the initiation of treatment cause more complications, more disease transmission, and higher mortality. An untreated smear-positive TB case can infect 10 more patients in a year and more than 20 patients during its natural course until death (11). Healthcare-seeking behavior is an influential factor in the diagnosis and prognosis of MDR-TB (12). Patient delays and diagnostic delays depend on patterns of care-seeking of a patient. In South Asia, patients usually visit informal healthcare providers as the first point of care (13). Drug sellers, traditional healers, village doctors, ayurvedic, and homeopaths are recognized as informal healthcare providers in Bangladesh(14). About 60.7% of Bangladeshi patients usually seek first care from pharmacies or traditional providers(15). The number of care-seeking points is usually more as the patients shift from one provider to another until the final diagnosis from the DOTS center which is the diagnostic point of DR-TB. The number of Care seeking points have a greater influence on delay among patients (16). Moreover, among the healthcare providers, the likelihood of initial suspicion about the diagnosis of TB was found low (17). Additionally, social stigma, fear of isolation, and misbelief also cause delays in care-seeking and causes patient delays(18). Gender, education, geography, and socio-economic condition are some contributing factors that determine the care-seeking behavior of DR-TB in sub-Saharan Africa(19).

A study in India found a median patient delay of 25 days for uncomplicated pulmonary TB patients (20). In Bangladesh, the median health system delay was found 7.1 weeks and the median treatment initiation delay was found 10 days among MDR-TB patients in a previous study conducted in 2012-2013 (21). WHO recommends no more than 1-day delay for screening to diagnosis and diagnosis to treatment initiation Policy on TB infection control (22). Few authors suggested that a one-month total delay is acceptable while others suggested the total delay should not exceed two months (23). However, very few studies assessed the possible factors related to healthcare-seeking behavior and different delays of DR-TB patients as a whole and particularly from Bangladesh.

The aim of this study was to assess healthcare-seeking behaviors and delays of drugresistance tuberculosis patients. The evidence from this study will be useful for TB control program to take different specific measure at all levels of health systems and in the community level as necessary, to reduce different delays and to implement the END TB strategy by 2030 successfully.

#### Methods

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Setting and Study population

We conducted a prospective cross-sectional study, country wide, to reach the objectives. A quantitative survey design was adopted using the prospective cross-sectional approach. In Bangladesh, there are 46 chest clinics, one 250-bedded dedicated TB hospital, several medical college hospitals, and one specialized chest disease hospital for treating TB. We purposefully selected four centers where the flow of TB and DR-TB cases were the most among all centers (24). This study was conducted at the National Institute of Diseases of Chest and Hospital (NIDCH), Dhaka; Mymensingh Tuberculosis and Leprosy hospital; Netrakona Tuberculosis and Leprosy hospital; and Tangail Tuberculosis and Leprosy hospital (Figure-1). A few DR-TB patients (13) were interviewed in nearby Upazilla health complexes (UHC) and adjoining communities of respective catchment areas of enrolled TB hospitals in Netrakona and Tangail also to reach the estimated sample size of 92. The patients from the community were identified from the MDR-TB register of the International Nongovernmental organization (INGO) - Damien Foundation (DF), as they were under treatment from DF. The NIDCH is the tertiary public hospital in Mohakhali, Dhaka. This is the top referral hospital for DR-TB in Bangladesh. There are 685 beds while 70 beds are reserved for DR-TB patients(25). GF works in 17 countries in Asia. In Bangladesh, they are working in the field of leprosy and TB in collaboration with the National Tuberculosis Control Program (NTP) of Bangladesh. They have three referral hospitals for MDR-TB treatment. This study was conducted in all three referral TB hospitals managed by the DF, which comprises of total 255 beds in Tangail (95 beds), Mymensingh (100 beds), and Netrakona (60 beds) (26).

Figure 1: Map of study site locations presenting the distribution of different delays among

DR-TB patients in Bangladesh

From 17<sup>th</sup> November to 7<sup>th</sup> December 2018, all DR-TB patients admitted to the four selected TB hospitals and community patients available from the near the catchment areas of TB hospitals in Tangail and Netrakona during the time of the survey were considered as the study population. Patients with DR-TB were bacteriologically confirmed, either by GeneXpert or culture. The study comprised patients aged 16 or older who were registered with NTP. All forms of DR-TB treatment registration groups were covered. Patients with severe illnesses were excluded from our study.

A total of 41 patients were from NIDCH, 23 from Mymensingh TB hospital, 9 from Tangail, and 6 from Netrakona TB hospital. Moreover, 13 available DR-TB patients were interviewed from the catchment areas of Netrakona and Tangail TB hospitals.

### Study tools and data collection

A pretested structured survey questionnaire was used to conduct face-to-face interviews. The health care seeking questionnaire was adopted from the WHO document "Diagnostic and treatment delay in tuberculosis- An in-depth analysis of the health-seeking behavior of patients and health system response in seven countries of the Eastern Mediterranean Region"(27). The questionnaire was translated into the local language Bangla and then again back translated into English to check the accuracy and consistency of the tool. The questionnaire was modified according to the pretesting experiences as per the consensus of the research team. Hospital records were reviewed from the DR-TB card, Sputum register, TB register and Laboratory log to source match the credentials of the hospital admitted study participants as well as participants from catchment areas. Two researchers and three trained research assistants with medical backgrounds who were good in the local language conducted all the interviews. After interviewing each DR-TB patient, the TB-card was reviewed for validation of patient information and for some key information like treatment

registration group, date of diagnosis and date of treatment, etc. Any conflict between patient response and data records, record data was preferred to reduce recall bias.

# Operational definitions

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

Resistance against one or more anti-TB drugs was considered as DR-TB. It can be single-drug resistant, multi-drug resistant, or extensive drug-resistant. Resistance against the first-line anti-TB drug, Rifampicin (RFP) and Isoniazid (INR) was considered as MDR-TB. The patients who had never been treated for TB before were categorized as new MDR-TB. The patients who were previously treated for TB and were declared as cured were considered as relapse-MDR-TB. The patients who were previously treated for TB but could not complete or lost to follow up (LTFU) were categorized as re-treatment MDR-TB. When a patient previously received TB treatment but the outcome of the treatment was unknown or undocumented, known as other-MDR-TB (24). Resistant against first-line anti-TB drugs with the resistance of one fluoroguinolone and a second-line injectable drug (aminoglycosides and capreomycin) was categorized as XDR-TB. The participants were asked about the date of the onset of the first symptom regarding TB, the date of the first care-seeking from any providers, the date of diagnosis, and the date of treatment initiation. Patient delay was considered as the time between the onset of symptoms of TB identified by a patient to the first care-seeking from any healthcare provider (20). The time between first care-seeking by a patient and being confirmed diagnosed with DR-TB by GeneXpert/Culture was considered as Diagnostic delay (28). Treatment delay was defined as the time between a patient diagnosed with DR-TB and initiation of DR-TB treatment by healthcare providers(27). The time between a patient first recognizing his/her symptoms of DR-TB and getting initiation of treatment was calculated as total delay (20) (Fig. 2). Delay more than the median value considered as long delay.

Figure 2: Definition of different delays (27) (28).

According to the NTP guideline of Bangladesh, all DR-TB patients are leveled with the different treatment registration groups- new cases, relapse cases, failure of treatment by 1<sup>st</sup> line drug (F1), failure of treatment by 1<sup>st</sup> line drug due to loss to follow-up, failure of retreatment by 1<sup>st</sup> line drugs (F2), other cases and XDR-TB. New cases were labeled as those who had no previous history of TB. Relapse cases are those who had a history of TB, but treatment was completed and cured. Other cases were labeled who had a history of TB but no documents of taking or completement of drugs. Doctors, both public and private and DOTS providers are defined as formal healthcare providers in this study. Drug sellers, Village doctors (LMF), Traditional healers, Homeopaths, and Ayurvedic were defined as informal healthcare providers. Self-care at home was also categorized as informal care.

### Data analysis

All data were entered and cleaned through MS excel (Microsoft Office Professional Plus 2021, Microsoft Corporation, Washington, United States) and analyzed through STATA version 16.0 (StataCorp,4905, Lakeway Drive, College Station, Texas 77,845, USA). Descriptive analysis of Socio-demographic characteristics, clinical and personal profile was done using frequency and percentages. Delays were measured using median and range. We performed univariable logistic regression analysis for all predictive factors for different delays and odds ratios (ORs), and 95 % confidence intervals (CI) were calculated. Patient delay was calculated from patient recall. Diagnostic delay was calculated by subtracting patient delay from the date of diagnosis collected from the TB card. Treatment delay was calculated by subtracting the date of diagnosis from the date of treatment initiation collected from the hospital records.

#### Ethical approval

Ethical approval was obtained from the institutional review board (IRB) of James P. Grants School of Public Health, BRAC University under reference number 2018-40-IR. Formal permission was also taken from the head office of Damien Foundation Bangladesh and respective hospital management. Informed written consent was ensured for all respondents over eighteen years after verbal explanation about the study. Informed written consent was taken from parents and assent was taken from respondents under eighteen years of age. Thumbprint was taken, those who were illiterate. The anonymity and confidentiality of all respondents were well-maintained. Personal protective equipment (PPE) including N95 masks was used while interviewing. For community patients, interviews were taken from the nearest directly observed treatment, short-course (DOTS) centers. Transport costs were provided to the community participants.

Result

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

Among the total of 92 patients interviewed, 25 (27.17%) were new MDR-TB, 29 (31.52%) were Relapse-MDR-TB, 33 (35.87%) were Re-treatment-MDR-TB, 3 (3.26%) were XDR-TB and 2 (2.17%) were other MDR-TB patients. Among the participants, 69 (75%) were men, 45 (48.91%) patients were 16-34 years of age and most of them 66 (71.74%) were living in rural areas. Most participants were married 76 (82.61%) and engaged in manual work 40 (43.48%). Most of the patients 42 (45.65%) had never attended school. The majority were previously smokers 47 (51.09%) while 15 (16.30%) were found current smokers. The larger portion of the participants 38 (41.30%) had a family income range between 10001-20000 BDT. Very few of them were alcoholics 6 (6.52%) while 16 (17.39%) had diabetes and 10 (10.87%) had other co-morbid diseases. The history of the previous TB infection was present among 62 (67.39%) patients while 60 (65.22%) had BCG scar proving they were vaccinated. The most common symptoms presented by the patients at the time of first care-seeking from any healthcare provider were Fever 83 (90.22%) and Cough 78 (84.87%). Other major symptoms were weight loss 61 (66.30%), Haemoptysis 12 (13.04%), Chest pain 23 (25%) and anorexia 10 (10.87%). Three or less symptoms were initially present among most of the 67 (72.83%) patients. The first healthcare provider, they consulted with was an informal provider in most cases 74 (81.32%). The majority of patients 56 (60.87%) sought care from more than four care-seeking points before getting a confirmatory diagnosis (Table-1).

# Table 1: Frequency distribution with sociodemographic factors, clinical symptoms, care

# seeking variables

256

257

Characteristics	Number of patients (%)
Sex	
Men	69 (75)
Women	23 (25)
Age (year)	45 (40.00)
16-34	45 (48.91)
35-54	23 (25.00)
≥55 B :1	24 (26.09)
Residence Rural	66 (71.74)
Urban	66 (71.74) 22 (23.91)
Semi-urban	04 (4.35)
Marital Status	04 (4.55)
Ever married	76 (82.61)
Never married	16 (17.39)
Employment	(2,103)
Unemployed	9 (9.78)
Sales & service	16 (17.39)
Business	10 (10.87)
Manual work	40 (43.48)
Housewife	9 (9.78)
Other	8 (8.70)
Educational status	
Not attended school	42 (45.65)
Primary	19 (20.65)
Secondary & above	31 (33.70)
Current smoker	15 (1620)
Yes	15 (16.30)
No No	77 (83.70)
Past smoker Yes	47 (51.09)
No	45 (48.91)
Family income (BDT)	43 (46.91)
≤10000	32 (34.78)
10001-20000	38 (41.30)
≥20000 ≥20000	22 (23.91)
Consume alcohol	<u> </u>
Yes	6 (6.52)
No	86 (93.48)
DM	, , ,
Yes	16 (17.39)
No	76 (82.61)
BCG scar	
Yes	60 (65.22)
No	21 (22.83)
Don't know	11 (11.96)
History of the previous TB	CO (CO OC)
Yes	62 (67.39)
No No	30 (32.61)
Number of care-seeking points	52 (57 (1)
≤5 >5	53 (57.61)
Co-morbid disease	39 (42.39)
Yes	10 (10.87)
No	82 (89.13)
Treatment registration group	02 (07.13)
New, MDR	25 (27.17)
Relapse, MDR	29 (31.52)
Re-treatment, MDR	33 (35.87)
Other, MDR	2 (2.17)
X-DR	3 (3.26)
Symptoms	
Fever	83 (90.22)
Cough	78 (84.78)
Weight loss	61 (66.30)
Chest pain	23 (25.00)
Chest pani	23 (23.00)
Hemoptysis	12 (13.04)
	·
	13   Page

Anorexia	10 (10.87)
Other	04 (4.35)
Number of initial symptoms	
≤3	67 (72.83)
>3	25 (27.17)
Type of first healthcare provider	
Formal	17 (18.68)
Informal	74 (81.32)
Number of care-seeking points	
≤4	36 (39.13)
>4	56 (60.87)

The median patient delay was found 7 (IQR 3,15) days. The median diagnostic delay was 88 (IQR 36.5, 210) days and the median treatment delay was 7 (IQR 4,12) days, while the total delay was 108.5 (IQR 57.5, 238) days. Before getting the diagnosis, the median number of care-seeking points was 5 (IQR 4,6) (Figure 2). The mean patient delay was 15.38 days. The mean diagnostic delay was 123.46 days, the mean treatment delay was 9.63 days, while the mean total delay was 148 days.

Figure 3: Median and IQR of Different delays among DR-TB patients in Bangladesh

Half of the (54.35%) DR-TB patients had more total delay while patients in NIDCH (63.41%) and Netrakona (62.50%) had the most. Most of the participants from Netrakona had more patients delay (50.00%), diagnostic delay (75.00%) and Treatment delay (62.50%) (Map-1, table-2).

Table 2: Percentage of DR-TB patients who had long delays according to the study sites\*

Long delays	NIDCH (%) n= 41	Mymensingh (%) n= 23	Tangail (%) n = 20	Netrakona (%) n = 8	Overall (%) n = 92
Patient delay	39.02	47.83	20.00	50.00	38.04
Diagnostic delay	65.85	47.83	50.00	75.00	52.17
Treatment delay	56.10	56.52	25.00	62.50	50.00
Total delay	63.41	47.83	40.00	62.50	54.35

\* The table shows the percentages of DR-TB patients who had long patients, diagnostic, treatment, and total delay according to the study sites. Patient delay > 7 days, diagnostic delay > 88 days, treatment delay > 7 days, and total delay > 108 days are considered as long delay.

The median patient delay varied in sex, age, marital status, occupation, monthly family income, and presence of co-morbid diseases. Men had nearly double the median patient delay of 14 (IQR 3,25) days than females 6 (IQR 3,10) days. The young adult group of age (16-34 years) had more patient delay 7 (IQR 3,15) days than the older age group 35-54 years of age (6.5 days) and ≥55 years of age (5.5 days). The ever-married patients had a more median patient delay of 7 (IQR 3,15) days than the never-married group of 5 (3-14.5) days. Unemployed persons had a median patient delay of 14 (IQR 3,15) days than other professionals such as manual workers, housewives, and businessmen. The person whose occupation was "Sales & Service", had a less median patient delay of 3.5 (IQR 3,7.5) days. The median patient delay was 4 (IQR 3,7) days among patients who had monthly family income ≥20,000 BDT while those who had monthly family income <20,000 BDT, had a patient delay of 7 (IQR 3,15) days. The patients who had comorbid diseases found less patient delay 4.5 (IQR 3,7) days while others had 7 (IQR 3,15) days (Table 3).

The median diagnostic delay was found more among men 102 (IQR 33,180) days than women 87 (IQR 39,224) days. Young adults (18-34 years of age) had more median diagnostic delay of 101.5 (IQR 36, 201) days than other age groups. Urban patients had less median diagnostic

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

delay of 60 (IQR 31, 129) days than rural patients 90 (37, 226) days. Patients who never married found more median diagnostic delay 125 (IQR 23.5, 211.5) days than ever married 84 (IQR 42, 206.5) days. Housewives had more median diagnostic delay 106 (IQR 62,142) days than other professions. Higher educated patients had a less diagnostic delay. Educated up to secondary and higher levels had a median diagnostic delay of 81 (IQR 36, 180) days. Current smokers had more delays 125 (IQR 60, 237) days than non-smokers 84 (IQR 36,194) days. Lower-income patients had a median diagnostic delay of 103 (IQR 56, 226) which was more than higher-income patients. Diabetic patients had less diagnostic delay 32 (IQR 23, 64) days than non-diabetic 98 (IQR 60, 222) days. The patient with a previous TB infection had a median diagnostic delay of 105 (IQR 62, 231) days which was more than those who didn't have pre-TB 39 (IQR 24, 89) days. The median diagnostic delay of 142 (IQR 72, 237) days was found among those who had number of care-seeking points more than 5 and 62 (IQR 30, 134) days who had the number of care-seeking points ≤5. The patients who sought first care from formal healthcare providers had less diagnostic of delay 39 (IQR 23, 106) days than who got care from informal providers 95 (IQR 51, 226) days. The patients with co-morbid disease had a median diagnostic delay of 67 (IQR 33, 98) days which was less than who didn't had comorbid diseases 90 (IQR 37, 219) days. The median diagnostic delay of the patients who had ≤3 initial symptoms was 80 (IQR 32.5, 174.5) days (Table 3). The median treatment delay was found more among men (8 days), ≥55 years of age (8 days), rural people (8 days), not attend school (8 days), who had previous TB infections (8 days), and who is manual workers (8 days) or occupation was "Sales & Service" (8.5 days). However, the patients who first seek care from formal providers (5.5 days) and patients with co-morbid diseases (6 days) were found to have less median treatment delay (Table 3).

The median total delay was found more among men (124 days), rural patients (108 days), Never married (141.5 days), housewives (134.5 days), manual workers (104 days), family income ≤10,000 BDT (129 days), patients who had pre-TB (119 days), number of care-seeking points more than 5 (176 days) and patients who had initial symptoms more than 3 (150 days). On the other side, the median total delay was comparatively less among ≥55 years of age (87 days), urban patients (68 days), who had diabetes (63 days), who first seek care from formal providers (67.5 days) and who had co-morbid diseases (75 days) (Table 3).

**Table 3**: Socio-demographic characteristics and personal history of DR-TB patients

Characteristics	N (%)	Patient delay	Diagnosis delay	Treatment initiation delay	Total Delay	
		Median d	elay (IQR) in days*	uem,		
Sex						
Women	69 (75)	6 (3-10)	87 (39-224)	6 (4-9)	104 (48-241)	
Men	23 (25)	14 (3-25)	102 (33-180)	8 (4-14)	124 (57.5-213.5)	
Age (year)	== (==)	- · (e = e)	102 (00 100)			
16-34	45 (48.91)	7 (3-15)	101.5 (36-201)	7 (4-11)	119 (55-240)	
35-54	23 (25.00)	6.5 (3-15)	96.5 (64-184)	7 (4-14)	115 (102-190)	
>55	24 (26.09)	5.5 (1.5-11)	64.5 (32-221.5)	8 (5-13.5)	87 (44-235.5)	
Residence					()	
Rural	66 (71.74)	7 (3-14)	90 (37-226)	8 (5-13)	108 (61-250)	
Urban	22 (23.91)	7 (3-30)	60 (31-129)	6 (3.5-12)	68 (45-162)	
Semi-urban	04 (4.35)	3 (1-6)	140.5(84.5-207.5)	4.5 (3.5-8)	149.5 (95-215.5)	
Marital Status	1 (111)	- ( -)	(* ** *** ****)		(* )	
Ever married	76 (82.61)	7 (3-15)	84 (42-206.5)	7 (4-11)	106 (62-234.5)	
Never married	16 (17.39)	5 (3-14.5)	125 (23.5-211.5)	8 (3.5-13.5)	141.5 (56-238.5)	
Employment						
Unemployed	9 (9.78)	14 (3-15)	52 (37-201)	6 (4-8)	61 (55-241)	
Sales & service	16 (17.39)	3.5 (3-7.5)	80 (24-222)	8.5 (4-12.5)	90 (42-236)	
Business	10 (10.87)	7 (3-15)	64 (30-81)	7 (4-9)	91 (47-120)	
Manual work	40 (43.48)	7 (3-10)	89.5 (60-224)	8 (4-17)	104 (78-240)	
Housewife	9 (9.78)	7 (1.5-20)	106 (62-142)	6 (5-8)	134.5 (88.5-189.5)	
Other	8 (8.70)	18 (6-30.5)	137 (56.5-255)	4 (3-8)	208.5 (68-296)	
Educational status	- (2111)	(	(* **** ***)	(= -2)	(****)	
Not attended school	42 (45.65)	6 (2-14)	87 (45-219)	8 (5-13)	103 (66.5-241)	
Primary	19 (20.65)	7 (3-15)	104 (60-222)	7 (3-13)	115 (81-162)	
Secondary & above	31 (33.70)	7 (3-15)	81 (36-180)	7 (3-11)	102 (48-241)	
Current smoker					/	
Yes	15 (16.30)	7 (4-15)	125 (60-237)	7.5 (5-11)	119 (78-255)	
No	77 (83.70)	7 (3-14.5)	84 (36-194)	7 (4-13)	104 (55-229)	
Past smoker		`	Ì ,	, , ,	`	
Yes	47 (51.09)	7 (2-10)	91 (37-231)	8 (4-14)	103 (54.5-246)	
No	45 (48.91)	7 (3-15)	85 (36-180)	7 (4-10.5)	111.5 (57.5-213.5)	
Family income (BDT)		` /	l ` ´	` ′		
≤10000	32 (34.78)	7 (3-15)	103 (56-226)	7 (4-9)	129 (81-242)	
10001-20000	38 (41.30)	7 (3-15)	60 (19-180)	8 (3.5-13)	82 (41-195)	
≥20000	22 (23.91)	4 (3-7)	96 (62-194)	7 (5-14)	106.5 (69-	
Consume alcohol			ì	ì	`	
Yes	6 (6.52)	3.5 (3-6)	258.5 (95-297)	7 (4-7)	236 (104-303)	
No	86 (93.48)	7 (3-15)	81 (33-184)	7.5 (4-13)	108 (55-229)	
DM		, ,		Ì	, , ,	

Healthcare seeking and delays in drug-resistant Tuberculosis patients in Bangladesh

***	16 (15 20)	7 (2 5 20)	22 (22 (4)	5.5 (2.0)	(2 (22 115)
Yes	16 (17.39)	7 (3.5-20)	32 (23-64)	5.5 (3-9)	63 (33-115)
No	76 (82.61)	7 (3-15)	98 (60-222)	8 (4-13)	112 (78-241)
BCG scar					
Yes	60 (65.22)	7 (2-10)	80.5 (37-180)	7 (3-11)	102 (58-224)
No	21 (22.83)	7 (3-15)	97.5 (21-201.5)	7.5 (5.5-18.5)	112 (33-229)
Don't know	11 (11.96)		180 (60-295)	7.5 (4-12)	201.5 (93-291.5)
History of the previous TB					
Yes	62 (67.39)	7 (3-12)	105 (62-231)	8 (4.5-11)	119 (84-252)
No	30 (32.61)	7 (3-21)	39 (24-89)	6 (4-14)	64.5 (42.5-145)
Number of care- seeking points		, ,			
<u>≤4</u>	53 (57.61)	7 (3-15)	62 (30-134)	7 (4-10.5)	78 (47-150)
>4	39 (42.39)	7 (3-15)	142 (72-237)	8 (4-16)	176 (90-255)
Number of initial	( /	. (= =)	( )	- ( - ,	( )
symptoms					
≤3	67 (72.83)	7 (3-15)	80 (32.5—174.5)	8 (5-13)	108 (58-224)
>3	25 (27.17)	6 (3-10)	143.5(53.5-239.5)	7 (3.5-8.5)	150 (55-242)
Type of first healthcare provider					
Formal	17 (18.68)	8 (3-30)	39 (23-106)	5.5 (2.5-10.5)	67.5 (34-145)
Informal	74 (81.32)	7 (3-14)	95 (52-226)	8 (4-13.5)	109 (63-250)
Co-morbid disease					
Yes	10 (10.87)	4.5 (3-7)	67 (33-98)	6 (4-9)	75 (55-98)
No	82 (89.13)	7 (3-15)	90 (37-219)	7.5 (4-12.5)	111.5 (57.5-240.5)
Treatment registration group					
New, MDR	25 (27.17)	7 (3-15)	36.5 (23-109)	5 (4-13)	57.5 (37.5-145)
Relapse, MDR	29 (31.52)	7 (3-10)	92.5 (30-238.5)	7.5 (4-11.5)	102 (47-255)
Re-treatment, MDR	33 (35.87)	5 (3-15)	105 (70-194)	8 (5.5-11)	119 (90-236)
Other, MDR	2 (2.17)	10.5 (7-14)	119 (37-201)	6.5 (4-9)	136 (48-224)
X-DR	3 (3.26)	21 (15-30)	81 (64-283)	19.5 (18-21)	215.5 (115-316)

In logistic regression analysis, the patient delay was found significantly associated with never married (OR=4.57, 95 % Cl=1.20-17.33), non-diabetic (OR=3.19, 95 % Cl=1.01-10.10) (Table-4). The diagnostic delay was significantly associated with the number of care-seeking points more than 4 (OR=3.33, 95% Cl=1.38-8.03), non-diabetic (OR=10.16, 95% Cl=2.15-47.90). No variable was found significantly associated with treatment delay. However, total delay was significantly associated with being non-diabetic (OR=5.65, Cl=1.49-21.45), and the number of care-seeking points was more than 4 (OR=3.79, 95% Cl=1.55-9.24).

# Table 4: Logistic regression analysis of the determinants of the patient, diagnostic,

# treatment, and total delay among the DR-TB patients

330

331

Variable	Categories	Patient included	Patio	ent delay	Diagr	ostic delay	Treati	ment delay	Т	otal Delay
		-	OR	95% CI	OR	95% CI	OR	95% CI	O R	95% CI
Sex	Male	69	1		1		1		1	
	Female	23	0.71	0.27-1.02	1.34	0.52-3.46	0.44	0.17-1.14	1.1	0.44-2.89
Age (year)	16-34	45	1		1		1		1	
	35-54	22	0.87	0.32-2.43	1.53	0.54-4.37	0.96	0.34-2.67	0.8	0.31-2.45
	55 and above	25	1.31	0.49-3.54	0.49	0.18-1.34	1.70	0.61-4.74	0.3	0.12-0.96
Education	No education	44	1		1		1		1	
	Primary	19	0.82	0.30-2.41	1.11	0.38-3.26	0.46	0.15-1.39	0.9	0.31-2.74
	Secondary & above	29	1.49	0.57-3.88	1.07	0.42-2.74	0.64	0.24-1.66	1.0	0.42-2.74
Residence	Rural	66	1		1		1		1	
	Urban	26	0.63	0.25-1.57	0.76	0.31-1.89	0.49	0.19-1.23	1	0.40-2.48
Smoke	Yes	15	1		1		1		1	
currently	No	77	1.05	0.35-3.18	0.90	0.30-2.72	0.46	0.13-1.57	0.6	0.53-4.21
Distance of	<5 km	59	1		1		1		1	
near health facility	≥5 km	33	0.57	0.24-1.35	1.50	0.64-3.55	0.77	0.32-1.82	0.9	0.39-2.13
Diabetes	Yes	16	1		1		1		1	
	No	76	3.19*	1.01- 10.10	10.16*	2.15-47.90	2.86	0.94-8.71	5.6 5*	1.49-21.4
BCG scar	Yes	52	1		1		1		1	
	No	40	0.73	0.32-1.68	1.32	0.58-3.02	1.59	0.68-3.72	1.4	0.62-3.26
Pre-TB	Yes	62	1		1		1		1	
	No	30	0.63	0.26-1.52	0.27	0.11-0.69	0.39	0.16-0.96	0.3 6	0.15-0.90
Complete	Yes	25	1		1		1		1	
previous treatment	No	39	2.55	0.91-7.15	1.26	0.45-3.48	1.13	0.39-3.23	1.4	0.53-4.08
Number of care-seeking	Less than or equal to 4	36	1		1		1		1	
point	More than 4	56	0.92	0.40-2.14	3.33*	1.38-8.03	1.49	0.64-3.48	3.7 9*	1.55-9.24
Гуре of	Formal	19	1		1		1		1	
provider at first point	Informal	73	1.09	0.39-3.00	2.08	0.73-5.88	1.78	0.65-4.94	1.1 4	0.41-3.14
<b>Freatment</b>	Primary	63	1		1		1		1	
registration group	Secondary	29	1.29	0.53-3.13	1.92	0.78-4.71	1.52	0.61-3.79	1.6 6	0.68-4.04
Marital	Ever married	76	1		1		1		1	
status	Never married	16	4.57*	1.20- 17.33	1.29	0.43-3.81	1.21	0.40-3.68	2.5 8	0.82-8.13
Consume	Yes	7	1		1		1		1	
Alcohol	No	85	8.17	0.94- 70.83	0.16	0.02-1.35	1.07	0.23-5.09	0.3 7	0.07-2.03
Consume	Yes	4	1		1		1		1	
substances	No	88	3.77	0.377- 37.67	0.33	0.03-3.33	0.46	0.05-4.59	0.3 2	0.03-3.18
mprisonmen	Yes	12	1		1		1		1	
	No	80	0.83	0.24-2.84	1.55	0.45-5.29	1.02	0.30-3.48	1	0.30-3.36
Contact with DR-TB	Yes No	26 56	0.36	0.13-1.01	1.35	0.53-3.42	0.90	0.35-2.33	0.9	0.36-2.34
	Don't know	10	0.30	0.03-0.79	1.17	0.27-5.02	0.63	0.14-2.72	0.3	0.08-1.74
		111	1117	0.03-0.79						U UX-1 /2

332

333

Asthma	Yes	10	1		1		1	0.25-3.59	1	
	No	82	1.21	0.33-4.52	1.65	0.43-6.30	0.94	0.25-3.59	2.5 7	0.62-10.65

#### Discussion

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

Healthcare-seeking patterns determine the progression, prognosis, and outcome of DR-TB patients. Choice of healthcare has a key role in the journey to get a cure. The first careseeking point is important as well as the number of providers. Bangladesh has a pluralistic health system where the coexistence of different stakeholders, including formal and informal healthcare providers, is usual(29). The referral system is not well-established, especially between informal to formal providers. This study revealed that most of the DR-TB patients (81.32%) were initially visited by informal providers, dominantly drug sellers (68.48%). Other informal providers were village doctors, traditional healers, homeopaths, ayurvedic, etc. Similar findings were found in other studies regarding care-seeking behaviors of TB/MDR-TB patients in Bangladesh(14)(30). A study among TB patients in India, Zimbabwe, and Ethiopia found that two-thirds of them sought first care from non-qualified professionals(31)(32)(33). Informal care providers usually treat with medicine without suggesting any investigations(15). Prescription of antibiotics irrationally is also common among them(34). Also, they don't refer patients to formal providers or DOTS centers. So, a large portion of the patients had more diagnostic delays found by this study. Patients seeking initial care from informal providers were found to have more than twice the median diagnostic delay, as those who seek care from formal providers. A previous study among TB patients found more health system delays (52%) who seek care from informal providers than formal providers (16%)(34). Policymakers should keep in mind this larger portion of the cakeinformal caregivers for effective control of DR-TB. Awareness programs should introduce, train them, and establish a referral system between informal to formal caregivers to reduce delays.

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

than formal healthcare settings.

The study calculated the number of care-seeking points from the initial symptom of DR-TB to confirmatory diagnosis. The median number of care-seeking points for DR-TB patients was found 5 which is more than in other countries like the USA-4, India-2, and Zimbabwe-3 (35) (33) (32). Care seekers from informal providers had more care-seeking points before diagnosis. More care-seeking points cause more diagnostic and health system delays. Ultimately, these phenomena cause a longer period of DR-TB transmission in the communities. Preventing this vicious cycle is of utmost need to control DR-TB in lowresource countries like Bangladesh. The median time between the onset of the first symptom of DR-TB and the first care-seeking was found 7 days in this study, which is the patient delay. No other study in Bangladesh calculated the patient delays among DR-TB patients. However, studies from other countries found more median patient delays among DR-TB/uncomplicated TB patients such as Zimbabwe- 26 days, Ethiopia- 35 days, China- 58 days (95% of cases), USA- 25 days, and India- 15 days(33)(31)(6)(36)(37). One of the reasons for the low patient delay found in our study is the operational definition. This study defined 'patient delay' as the time between the appearance of the first symptom to the first consultation with healthcare providers irrespective of their types- formal or informal, whether most of the study considered only formal providers(38). The healthcare system of many countries is not as pluralistic as Bangladesh. Seeking care from drug sellers is common in Bangladesh as there is no strict monitoring system though there is a provision of not selling drugs without the prescription of qualified professionals. Two out of five people in Dhaka the capital city of Bangladesh seek care from community pharmacies(39). From the patient perspective, at the community level, pharmacies/informal providers are nearer, less time-consuming, and more cost-effective

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

We found a median diagnostic delay of 88 days among the study participants. A previous study (2012-13) in Bangladesh among MDR-TB patients found a health system delay of 7.1 weeks while the provider's delay was only 4 weeks which is much lesser than the findings of this study(10). There was a possible role of informal providers for this variation. Very few participants (10.8%) in that study sought initial care from informal providers compared to the findings of our study (81.32%). Female participants (75% vs 33.3%), Rural participants (71.74%) vs 49.3%), and illiterates (45.65% vs 22%) were more in our study than Rifat et al. Moreover, 27.17% of the participants of this study were categorized as new MDR-TB while the previous study had only 2.4 %(40). The median diagnostic delay among MDR-TB patients in China was 84 days while in Zimbabwe 97 days(41)(6)(33) which was very similar. A previous study among TB patients found a diagnostic delay of 68.5 days in Bangladesh which is less than our study(15). Seeking care from informal providers at the first point, seeking care from multiple healthcare providers, or the tendency to switch providers several times contributes to diagnostic delay. On top of that, qualified healthcare providers occasionally didn't suggest investigations necessary for diagnosing DR-TB(11). The diagnostic delay is a key indicator of the health system. Reducing diagnostic delays through strengthening a pluralistic health system is a challenge for Bangladesh. This study found a median treatment initiation delay of 7 days. The median treatment initiation delays found previous studies was 9 days in China(42), 8 days in Gujrat, India(43) 13 days in Myanmar(44), 10 days in Bangladesh(21), 10-22 days in South Africa(45), 9-17 days in Russia(46), 7 days in Bhopal, India(47). The treatment initiation delays mostly occur due to repetition of confirmatory tests, baseline investigations before starting treatment, and sometimes an inadequate number of resident beds for DR-TB in tertiary hospitals(21). Also, the patient's seriousness about the disease due to lack of awareness and motivation is

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

another possible cause of delay(48). Treatment delay results in poor prognosis and risk of transmission of DR-TB bacilli to the community. However, the treatment initiation delays can be reduced by ensuring an adequate number of beds for DR-TB in all tertiary hospitals, ensuring proper counseling after diagnosis, and suggesting baseline investigations after admission of DR-TB patients into hospitals. The median total delay was 108.5 days in this study. Previous studies found the median diagnostic delay of 57 days in the USA(36), 120 days in China, 100 days in Pakistan(27), and 132 days in Zimbabwe. Rifat et al found a median of 7.1 weeks of health system delay among MDR-TB patients in Bangladesh in 2015(21). Another study among TB patients in Bangladesh found a total delay of 12 weeks(34). The patient delays, diagnostic delays, and treatment delays contribute to the length of total delays. Both patients and health systems are responsible for long total delays. During these delays, resistant tuberculosis bacilli are continuously spread from person to person. The patient's lung condition can worsen during this period. Thus, the prognosis of the disease becomes poor which contributes to treatment failure, higher mortality, and economic loss. The chance of fatality is very high in case of a long total delay(21). Being non-diabetic was significantly associated with patient, diagnostic, and total delays. In Bangladesh, most (over 50%) diabetic patients are registered with Bangladesh Diabetic Somity (BADAS) and seek care (95.2%) from private facilities of BADAS while only 4.3% seek care from informal providers(49). This scenario can clarify why diabetic patients had fewer delays than non-diabetics in Bangladesh. The patient's delay was significantly associated with never being married in this study. Unmarried people may have a lack of self-motivation and social support, this may be the possible reason for more patient delays among them (50). The number of care-seeking points more than 4 was found significantly associated with

diagnostic and total delays. This is obvious that more care-seeking points will contribute to more delays.

The strength of the study is that the investigators interviewed patients face to face. Thus, the information regarding different delays could easily validate with the patient's memory and record files. DR-TB patients are not available in abundance in the hospitals due to the low case detection rate in Bangladesh(51)(52). The study covered both rural and urban populations as well as non-government and government TB hospitals within certain geographic regions. There is also a possibility of recall bias regarding the patient delays and healthcare-seeking behavior, as researchers needed to rely on the patient's memory. However, most of the respondents were drawn from the intensive phase of treatment, so the recall period was lesser than community patients. Sometimes few medical records were found missing thus it was difficult to identify the date of diagnosis or treatment initiation. However, researchers had made an effort to minimize the discrepancies by checking all medical records available to patients and service records of hospitals. Few data regarding delays were missing as some patients could not remember the date of their first careseeking. So, calculation of total delays also was not possible for those patients. This missing data on patient delay did not affect the overall outcome of the study.

# Conclusion

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

Most of the DR-TB patients sought initial healthcare from informal providers while most of the patients seek care from more than five care-seeking points leading to more patient and diagnostic delays. Patient, diagnostic, and treatment initiation delays among the patients were more than recommended resulting in the transmission of the drug-resistant bacilli in the community and increasing the burden of the disease. Community-based interventions are necessary to ensure needful healthcare from formal providers and to reduce the number

of care-seeking points before diagnosis. Appropriate training and awareness among healthcare providers could reduce diagnostic delays. This study also recommends ensuring the availability of the Rapid diagnostic test e.g., GeneXpert in primary health care centers. The evidence could help the policymakers, public health specialists, and healthcare providers to improve the TB control program, ensure mass awareness to reduce patient delay, strengthen the health system to reduce diagnostic delay, and ensure early admission to reduce the treatment delay with a vision to the successful implementation of the "END TB 2030" strategy.

References

462

WHO. GLOBAL TUBERCULOSIS REPORT 2021 [Internet]. Available from: 463 1. 464 http://apps.who.int/bookorders. [cited 2022 Nov 22] Desissa F, Workineh T, Beyene T. Risk factors for the occurrence of multidrug-465 2. resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis 466 467 treatment in East Shoa, Ethiopia. BMC Public Health. 2018 Apr 2;18(1). WHO. THE END-TB STRATEGY. 2015; [Internet]. Available from: 468 3. https://www.who.int/publications/i/item/WHO-HTM-TB-2015.19. [cited 2022 Nov 469 470 22] Kidenya BR, Mshana SE, Fitzgerald DW, Ocheretina O. Genotypic drug resistance 471 4. using whole-genome sequencing of Mycobacterium tuberculosis clinical isolates 472 from North-western Tanzania. Tuberculosis. 2018; 473 Trauner A, Borrell S, Reither K, Gagneux S. Evolution of drug resistance in 474 5. tuberculosis: Recent progress and implications for diagnosis and therapy. Drugs. 475 476 2014; 477 6. Cheng S, Chen W, Yang Y, Chu P, Liu X, Zhao M, et al. Effect of Diagnostic and Treatment Delay on the Risk of Tuberculosis Transmission in Shenzhen, China: An 478 Observational Cohort Study, 1993-2010. PLoS ONE. 2013 Jun 27;8(6). 479 WHO. Rapid Communication: Key changes to the treatment of drug-resistant 480 7. tuberculosis. World Health Organization [Internet]. 2022;(WHO/UCN/TB/2022.2.):6. 481 Available from: 482

483 https://apps.who.int/iris/handle/10665/275383%oAhttp://apps.who.int/bookorders. 484 [cited 2022 Nov 22] 8. Van Cutsem G, Isaakidis P, Farley J, Nardell E, Volchenkov G, Cox H. Infection 485 Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key. 486 Clinical Infectious Diseases. 2016;62(Suppl 3):S238-43. 487 WHO. Global tuberculosis report 2018. 2018. 265 p. Available 488 9. from: https://apps.who.int/iris/handle/10665/274453. [cited 2022 Nov 22] 489 490 Rifat M, Hall J, Oldmeadow C, Husain A, Hinderaker SG, Milton AH. Factors related 10. to previous tuberculosis treatment of patients with multidrugresistant tuberculosis in 491 Bangladesh. BMJ Open. 2015; 492 Farah MG, Rygh JH, Steen TW, Selmer R, Heldal E, Bjune G. Patient and health care 493 11. system delays in the start of tuberculosis treatment in Norway. BMC Infectious 494 Diseases. 2006 Feb 24;6. 495 Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-496 12. prescription antimicrobial use worldwide: A systematic review. The Lancet Infectious 497 Diseases. 2011. 498 Sidharta SD, Yin JDC, Yoong JSY, Khan MS. High use of private providers for first 499 13. healthcare seeking by drug-resistant tuberculosis patients: A cross-sectional study in 500 Yangon, Myanmar. BMC Health Services Research. 2018 Apr 11;18(1). 501 502 Hossain S, Zaman K, Quaiyum A, Banu S, Husain A, Islam A, et al. Care seeking in 14. tuberculosis: Results from a countrywide cluster randomised survey in Bangladesh. 503

504 BMJ Open. 2014;4(5). Ehsanul Hug KATM, Moriyama M, Zaman K, Chisti MJ, Long J, Islam A, et al. Health 505 15. seeking behaviour and delayed management of tuberculosis patients in rural 506 Bangladesh 11 Medical and Health Sciences 1117 Public Health and Health Services. 507 BMC Infectious Diseases. 2018 Oct 12;18(1). 508 Law S, Piatek AS, Vincent C, Oxlade O, Menzies D. Emergence of drug resistance in 509 16. patients with tuberculosis cared for by the Indian health-care system: a dynamic 510 modelling study. The Lancet Public Health. 2017; 511 Megerso A, Deyessa N, Jarso G, Worku A. Lived experiences of tuberculosis patients 512 17. and their implications for early tuberculosis case identification and management in 513 pastoralist community setting: A qualitative study in Borena zone, Oromia region of 514 Ethiopia. BMC Health Services Research. 2020 Oct 9;20(1). 515 516 18. Atre SR, Mistry NF. Multidrug-resistant tuberculosis (MDR-TB) in India: An attempt 517 to link biosocial determinants. Vol. 26, Journal of Public Health Policy. 2005. p. 96-518 114. Sullivan BJ, Esmaili BE, Cunningham CK. Barriers to initiating tuberculosis treatment 519 19. in sub-Saharan Africa: A systematic review focused on children and youth. Vol. 10, 520 521 Global Health Action. Taylor and Francis Ltd.; 2017. Mistry N, Rangan S, Dholakia Y, Lobo E, Shah S, Patil A. Durations and delays in care 522 20. seeking, diagnosis and treatment initiation in uncomplicated pulmonary 523

Tuberculosis patients in Mumbai, India. PLoS ONE. 2016 Mar 1;11(3).

524

525	21.	Rifat M, Hall J, Oldmeadow C, Husain A, Milton AH. Health system delay in
526		treatment of multidrug resistant tuberculosis patients in Bangladesh. BMC Infectious
527		Diseases. 2015 Nov 16;15(1).
528	22.	WHO 2009. Global tuberculosis control: a short update to the 2009 report. World
529		Health Organization. 2009; Available from:
530		https://apps.who.int/iris/handle/10665/44241 [cited 2022 Nov 22]
531	23.	Pirkis JE, Speed BR, Yung AR, Dunt DR, Macintyre CR, Plant AJ. Time to initiation of
532		anti-tuberculosis treatment. Vol. 77, Tubercle and Lung Disease. 1996.
533	24.	National Tuberculosis Control Programme. National Guidelines and Operational
534		Manual for Programmatic Management of Drug Resistant TB [Internet]. 2020 [cited
535		2022 Jun 6]. Available from: https://www.ntp.gov.bd/guidelines/
536	25.	Banu S, Mahmud AM, Rahman MT, Hossain A, Uddin MKM, Ahmed T, et al.
536 537	25.	Banu S, Mahmud AM, Rahman MT, Hossain A, Uddin MKM, Ahmed T, et al.  Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of
	25.	
537	25. 26.	Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of
537 538		Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh. PLoS ONE. 2012;7(7).
<ul><li>537</li><li>538</li><li>539</li></ul>		Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh. PLoS ONE. 2012;7(7).  Damien Foundation. Annual Report 2017 [Internet]. 2017 [cited 2022 Sep 1].
<ul><li>537</li><li>538</li><li>539</li><li>540</li></ul>	26.	Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh. PLoS ONE. 2012;7(7).  Damien Foundation. Annual Report 2017 [Internet]. 2017 [cited 2022 Sep 1].  Available from: www.damienfoundation-bd.com
<ul><li>537</li><li>538</li><li>539</li><li>540</li><li>541</li></ul>	26.	Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh. PLoS ONE. 2012;7(7).  Damien Foundation. Annual Report 2017 [Internet]. 2017 [cited 2022 Sep 1].  Available from: www.damienfoundation-bd.com  World Health Organization. Diagnostic and treatment delay in tuberculosis. World
<ul><li>537</li><li>538</li><li>539</li><li>540</li><li>541</li><li>542</li></ul>	26.	Multidrug-resistant tuberculosis in admitted patients at a tertiary referral hospital of Bangladesh. PLoS ONE. 2012;7(7).  Damien Foundation. Annual Report 2017 [Internet]. 2017 [cited 2022 Sep 1].  Available from: www.damienfoundation-bd.com  World Health Organization. Diagnostic and treatment delay in tuberculosis. World Health Organization. 2006; Available from:

546 Ahmed SM. Exploring health-seeking behaviour of disadvantaged populations in 29. rural Bangladesh. Karolinska University Press. 2005. 547 Ahmed SM. Exploring health-seeking behaviour of disadvantaged populations in 548 30. rural Bangladesh. Karolinska Institutet; 2005. 549 Desissa F, Workineh T, Beyene T. Risk factors for the occurrence of multidrug-550 31. resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis 551 treatment in East Shoa, 2018;1-6. 552 Kapoor SK, Raman AV, Sachdeva KS, Satyanarayana S. How did the TB patients 553 32. reach DOTS services in Delhi? a study of patient treatment seeking behavior. PLoS 554 555 ONE. 2012 Aug 6;7(8). Tadokera R, Huo S, Theron G, Timire C, Manyau-Makumbirofa S, Metcalfe JZ. Health 556 33. care seeking patterns of rifampicin-resistant tuberculosis patients in Harare, 557 Zimbabwe: A prospective cohort study. PLoS ONE. 2021 Jul 1;16(7 July). 558 Sizear MMI, Nababan HY, Siddique MK Bin, Islam S, Paul S, Paul AK, et al. 559 34. Perceptions of appropriate treatment among the informal allopathic providers: 560 Insights from a qualitative study in two peri-urban areas in Bangladesh. BMC Health 561 Services Research. 2019 Jun 26;19(1). 562 Almeida CPB de, Skupien EC, Silva DR. Health care seeking behavior and patient 563 35. delay in tuberculosis diagnosis. Cadernos de Saúde Pública. 2015; 564 565 36. Sherman LF, Fujiwara PI, Cook † S V, Bazerman LB, Frieden TR. Patient and health care system delays in the diagnosis and treatment of tuberculosis. Vol. 3, INT J 566

TUBERC LUNG DIS. 1999.

568

569

570

- 37. Mistry N, Rangan S, Dholakia Y, Lobo E, Shah S. Durations and Delays in Care Seeking, Diagnosis and Treatment Initiation in Uncomplicated Pulmonary

  Tuberculosis Patients in Mumbai, India. 2016;1–17.
- 571 38. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and 572 treatment of tuberculosis. BMC Public Health. 2008.
- 573 39. Chowdhury F, Sturm-Ramirez K, Mamun A Al, Iuliano AD, Chisti MJ, Ahmed M, et al.

  574 Effectiveness of an educational intervention to improve antibiotic dispensing

  575 practices for acute respiratory illness among drug sellers in pharmacies, a pilot study

  576 in Bangladesh. BMC Health Services Research. 2018 Aug 31;18(1).
- 577 40. Rifat M, Hall J, Oldmeadow C, Husain A, Hinderaker SG, Milton AH. Factors related 578 to previous tuberculosis treatment of patients with multidrug-resistant tuberculosis 579 in Bangladesh. Available from: http://dx.doi.org/10.1136/bmjopen-2015-008273
- Zhang X, Yin J, Li H, Li S, Walley J, Zou G, et al. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study. Tropical Medicine and International Health. 2015;20(11):1431–7.
- Zhang X, Yin J, Li H, Li S, Walley J, Zou G, et al. Diagnostic and treatment delays of multidrug-resistant tuberculosis before initiating treatment: a cross-sectional study. Tropical Medicine and International Health. 2015;20(11):1431–7.
- 586 43. Shewade HD, Shringarpure KS, Parmar M, Patel N, Kuriya S, Shihora S, et al. Delay 587 and attrition before treatment initiation among MDR-TB patients in five districts of

Gujarat, India. Public Health Action. 2019 Feb 5;8(2):59–65.

588

589

590

591


592

- 44. Htun YM, Khaing TMM, Yin Y, Myint Z, Aung ST, Hlaing TM, et al. Delay in diagnosis and treatment among adult multidrug resistant tuberculosis patients in Yangon Regional Tuberculosis Center, Myanmar: a cross-sectional study. BMC health services research. 2018;
- 593 45. Cox H, Dickson-Hall L, Ndjeka N, van't Hoog A, Grant A, Cobelens F, et al. Delays and
  594 loss to follow-up before treatment of drug-resistant tuberculosis following
  595 implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
  596 PLoS Medicine. 2017;
- 597 46. P. E, G. B, E. N, A. G, E. B, D. E, et al. The impact of a line probe assay based
  598 diagnostic algorithm on time to treatment initiation and treatment outcomes for
  599 multidrug resistant TB patients in Arkhangelsk Region, Russia. PLoS ONE. 2016;
- Shewade HD, Shringarpure KS, Parmar M, Patel N, Kuriya S, Shihora S, et al. Delay and attrition before treatment initiation among MDR-TB patients in five districts of Gujarat, India. Public Health in Action. 2018;
- Nigam S, Sharma RK, Yadav R, Rao VG, Mishra P, Lingala MA, et al. Experiences and needs of patients with MDR/XDR-TB: A qualitative study among Saharia tribe in Madhya Pradesh, Central India. BMJ Open. 2021 Aug 12;11(8).
- Bhowmik B, Siddiquee T, Ahmed T, Afsana F, Samad MA, Pathan F, et al. Diabetes


  Care During 50 Years of Bangladesh. Bangladesh J Diabetol [Internet]. 2021;12:383–

  90. Available from: http://www.journalofdiabetology.org


609 Wang W, Wang F, Peng Y, Liu K, Chen X, Chai C, et al. Factors associated with 610 health-seeking preference among people who were supposed to cough for more than 2 weeks: A cross-sectional study in Southeast China. Patient Preference and 611 Adherence. 2020;14:1173-83. 612 WHO. REPORT: Global Tuberculosis Report 2013. Geneva: World Health 613 51. 614 Organization. 2013. Available from: https://apps.who.int/iris/handle/10665/91355. [cited 2022 Nov 22] 615 WHO. TUBERCULOSIS GLOBAL REPORT 2018. Geneva: World Health Organization; 616 52. 2018. Available from: <a href="https://apps.who.int/iris/handle/10665/274453">https://apps.who.int/iris/handle/10665/274453</a>. [cited 2022 Nov 617 618 22] 619



Map of study site locations presenting the distribution of differe



# Definition of different delays



Median and IQR of Different delays among